Lee J.-JLiao A.TTAI-CHING LIAOJIH-JONG LEESHANG-LIN WANG2022-04-252022-04-25202120762615https://www.scopus.com/inward/record.uri?eid=2-s2.0-85111021129&doi=10.3390%2fani11082199&partnerID=40&md5=9652ac7f5c635d03cb7e8d8ffee926dbhttps://scholars.lib.ntu.edu.tw/handle/123456789/605989Cyclophosphamide exhibits the weakest therapeutic effect compared with vincristine and doxorubicin in the CHOP (C, cyclophosphamide; H, doxorubicin; O, vincristine; and P, prednisolone) chemotherapeutic protocol for the treatment of canine lymphoma. Twenty dogs with multicentric lymphoma were treated using the LHOP protocol, which used l-asparaginase in place of cyclophos-phamide, and the outcomes were historically compared with those of dogs that received CHOP chemotherapy in the same institution. No significant differences were found in age (p = 0.107), body weight (p = 0.051), sex (p = 0.453), clinical stage V (p = 1), substage b (p = 0.573), T-cell phenotype (p = 0.340), overall response (p = 1), and hypercalcaemia status (p = 1) between the LHOP and CHOP groups. The adverse effects of l-asparaginase were well tolerated and self-limiting. The median PFS (progression-free survival) and median ST (survival time) in the LHOP group were 344 days (range: 28–940 days) and 344 days (range: 70–940 days), respectively. The median PFS and median ST in the CHOP group were 234 days (range: 49–1822 days) and 314 days (range: 50–1822 days), respectively. The dogs that received LHOP chemotherapy had a significantly longer PFS than the dogs that received CHOP chemotherapy (p = 0.001). No significant difference was observed in ST between the LHOP and CHOP groups (p = 0.131). Our study findings thus indicate that the LHOP protocol can be used as a first-line chemotherapeutic protocol in canine multicentric lymphoma. ? 2021 by the authors. Licensee MDPI, Basel, Switzerland.CanineL-asparaginaseLymphosarcomaOncologyOutcomejournal article10.3390/ani110821992-s2.0-85111021129